RxDoctor Payments Data

Randall Richwine, DO

Family Medicine · Fort Worth, TXNPI 1710910740

Payments from drug & device makers

$794,130in general payments, 2019–2025

Across 916 payments — averaging $866.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$407K
  • Kowa Research Institute, Inc.$156K
  • Exact Sciences$89K
  • Bayer$56K
  • Boehringer Ingelheim$28K
  • Janssen Research & Development, LLC$17K
  • plus $40K from 54 others

What the payments were for

  • Consulting fees$6,98223%
  • Speaking & faculty fees$9,03530%
  • Travel & lodging$1,6045%
  • Food & beverage$12,41541%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis22$407,291
Kowa Research Institute, Inc.41$156,332
Exact Sciences23$88,617
Bayer71$55,733
Boehringer Ingelheim67$28,291
Janssen Research & Development, LLC10$17,487
Pfizer(2 entities)103$15,571
AstraZeneca49$12,302
Novo Nordisk66$2,563
Sanofi-aventis U.S. LLC31$2,441
AbbVie(2 entities)67$972
Lilly USA, LLC62$738
Eisai Inc.14$712
GSK40$625
Corium, LLC20$479
Astellas Pharma US Inc20$401
Tris Pharma Inc19$355
Amgen18$266
Dexcom, Inc.10$201
Antares Pharma, Inc.13$197
Merck19$195
Biohaven Pharmaceutical Holding Company Ltd.13$192
Takeda Pharmaceuticals U.S.A., Inc.10$189
Amarin Pharma, Inc.14$181
Inspire Medical Systems, Inc.3$152
Nalu Medical, Inc.1$145
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC8$131
Biohaven Pharmaceuticals, Inc.5$127
Johnson & Johnson(3 entities)7$115
Abbott5$105
Otsuka America Pharmaceutical, Inc.6$100
Corcept Therapeutics4$76
Supernus Pharmaceuticals, Inc.4$65
Ironshore Pharmaceuticals Inc.4$61
Phathom Pharmaceuticals, Inc.5$61
Genentech USA, Inc.5$60
Shire North American Group Inc4$58
Halozyme Inc3$57
Lundbeck LLC2$34
Dynavax Technologies Corporation2$34
Axsome Therapeutics, Inc.2$34
Sanofi Pasteur Inc.2$34
Xeris Pharmaceuticals, Inc.2$31
Tolmar, Inc.2$28
Ultragenyx Pharmaceutical Inc.2$26
Olympus America Inc.1$26
Tactile Systems Technology Inc1$23
Adlon Therapeutics L.p.1$19
Globus Medical1$18
Pacira Therapeutics, Inc.1$18
IBSA Pharma Inc.1$17
Kaleo, Inc.1$17
Kowa Pharmaceuticals America, Inc.1$16
Seqirus USA Inc1$16
Si-bone, Inc.1$16
Medtronic1$15
Idorsia Pharmaceuticals US Inc1$15
Collegium Pharmaceutical, Inc.1$14
Nabriva Therapeutics, PLC1$12
Endo Pharmaceuticals Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794,130 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$43,726
Medicare patients
142
Services billed
879

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin101$107,742
OzempicSemaglutide71$92,739
EliquisApixaban56$62,716
XareltoRivaroxaban38$36,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$34,231
RybelsusSemaglutide26$31,731
FarxigaDapagliflozin Propanediol26$28,388
MounjaroTirzepatide19$22,371
TrulicityDulaglutide11$18,606
JanumetSitagliptin Phos/Metformin Hcl19$17,415
Tresiba Flextouch U-200Insulin Degludec11$12,447
Bydureon BciseExenatide Microspheres11$9,128
Levemir FlexpenInsulin Detemir23$7,319
SymbicortBudesonide/Formoterol Fumarate23$6,086
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen141$3,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,563$124,47097 claims
Boehringer IngelheimJardiance$28,291$107,742101 claims
PfizerEliquis$15,571$62,71656 claims
Lilly USA, LLCMounjaro, Trulicity$738$40,97730 claims
Johnson & JohnsonXarelto$115$36,72838 claims
AstraZenecaFarxiga, Symbicort$12,302$34,47449 claims
GSKTrelegy Ellipta$625$34,23145 claims
MerckJanumet$195$17,41519 claims
AbbVieSynthroid$972$1,38522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →